Cyclosporine-induced hypertension in cardiac transplantation.
Cyclosporine-induced hypertension occurs in more than 90% of patients following cardiac transplantation. This article underlines the clinical characteristics as well as the mechanisms that can be associated with the development of cyclosporine-induced hypertension. In addition, the clinical trials up to date for the treatment of hypertension following cardiac transplantation are discussed. However, in view of the possible long-term sequelae associated with cyclosporine-induced hypertension, further studies to evaluate the long-term efficacy and safety of antihypertensive agents and finally the long-term effects of hypertension on the cardiac allograft are needed.
Ventura
H O
HO
Department of Internal Medicine, Ochsner Medical Institutions, New Orleans, Louisiana, USA.
Mehra
M R
MR
Stapleton
D D
DD
Smart
F W
FW
D000959:Antihypertensive Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000009:adverse effects*; D016027:Heart Transplantation; D006801:Humans; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy; D011183:Postoperative Complications / Q000139:chemically induced* / Q000188:drug therapy; D013564:Sympathetic Nervous System / Q000187:drug effects
D000959:Antihypertensive Agents; D016572:Cyclosporine